Gilead patent partially upheld by EPO, Teva and STADA's challenge continues
MLex Summary: The European Patent Office's Technical Board of Appeal has partially upheld Gilead Sciences Inc’s EP 3,150,586, which covers compounds that enhance the performance of other drugs. The board revoked...To view the full article, register now.
Already a subscriber? Click here to view full article